Sigma's Double-Digit EPS Growth Lures New Bull -- Market Talk

Dow Jones

Nov 20

0111 GMT - Sigma Healthcare gets a new bull at UBS on the prospect of multiyear double-digit EPS growth. Initiating coverage of the stock with a buy rating, analyst Shaun Cousins tells clients that the pharmaceutical supplier's reverse takeover by the Chemist Warehouse retail group has created a capital-light business that justifies its elevated consensus multiple of 46.4X fiscal 2026 earnings. He writes in a note that operating leverage, sourcing and synergies will expand Sigma's underlying EBIT margin from fiscal 2025's pro forma 9.4% to 11.6% by fiscal 2030. UBS places a A$3.40 target price on the stock, which is up 1.0% at A$2.95. (stuart.condie@wsj.com)

(END) Dow Jones Newswires

November 19, 2025 20:11 ET (01:11 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2584970086"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2584970086\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2584970086?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-20 09:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584970086","market":"sh","top_or_hot":-1,"title":"Sigma's Double-Digit EPS Growth Lures New Bull -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0111 GMT - <a href=\"https://laohu8.com/S/SIGGF\">Sigma Healthcare</a> gets a new bull at UBS on the prospect of multiyear double-digit EPS growth. Initiating coverage of the stock with a buy rating, analyst Shaun Cousins tells clients that the pharmaceutical supplier's reverse takeover by the Chemist Warehouse retail group has created a capital-light business that justifies its elevated consensus multiple of 46.4X fiscal 2026 earnings. He writes in a note that operating leverage, sourcing and synergies will expand Sigma's underlying EBIT margin from fiscal 2025's pro forma 9.4% to 11.6% by fiscal 2030. UBS places a A$3.40 target price on the stock, which is up 1.0% at A$2.95. (stuart.condie@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 19, 2025 20:11 ET (01:11 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sigma's Double-Digit EPS Growth Lures New Bull -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSigma's Double-Digit EPS Growth Lures New Bull -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-20 09:11</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0111 GMT - <a href=\"https://laohu8.com/S/SIGGF\">Sigma Healthcare</a> gets a new bull at UBS on the prospect of multiyear double-digit EPS growth. Initiating coverage of the stock with a buy rating, analyst Shaun Cousins tells clients that the pharmaceutical supplier's reverse takeover by the Chemist Warehouse retail group has created a capital-light business that justifies its elevated consensus multiple of 46.4X fiscal 2026 earnings. He writes in a note that operating leverage, sourcing and synergies will expand Sigma's underlying EBIT margin from fiscal 2025's pro forma 9.4% to 11.6% by fiscal 2030. UBS places a A$3.40 target price on the stock, which is up 1.0% at A$2.95. (stuart.condie@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 19, 2025 20:11 ET (01:11 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SIG.AU","symbol_name":"SIGMA HEALTHCARE LTD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2584970086","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584970086","pubTimestamp":1763601060,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0111 GMT - Sigma Healthcare gets a new bull at UBS on the prospect of multiyear double-digit EPS growth. Initiating coverage of the stock with a buy rating, analyst Shaun Cousins tells clients that the pharmaceutical supplier's reverse takeover by the Chemist Warehouse retail group has created a capital-light business that justifies its elevated consensus multiple of 46.4X fiscal 2026 earnings. He writes in a note that operating leverage, sourcing and synergies will expand Sigma's underlying EBIT margin from fiscal 2025's pro forma 9.4% to 11.6% by fiscal 2030. UBS places a A$3.40 target price on the stock, which is up 1.0% at A$2.95. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SIG.AU":"SIGMA HEALTHCARE LTD","BK7103":"保健护理产品经销商"},"translate_title":"Sigma两位数的每股收益增长吸引了新的牛市——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SIG.AU":0.9},"content_text":"0111 GMT - Sigma Healthcare gets a new bull at UBS on the prospect of multiyear double-digit EPS growth. Initiating coverage of the stock with a buy rating, analyst Shaun Cousins tells clients that the pharmaceutical supplier's reverse takeover by the Chemist Warehouse retail group has created a capital-light business that justifies its elevated consensus multiple of 46.4X fiscal 2026 earnings. He writes in a note that operating leverage, sourcing and synergies will expand Sigma's underlying EBIT margin from fiscal 2025's pro forma 9.4% to 11.6% by fiscal 2030. UBS places a A$3.40 target price on the stock, which is up 1.0% at A$2.95. (stuart.condie@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 19, 2025 20:11 ET (01:11 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}